Waleed A Bayoumi

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 5

Top Topics

Tyrosine Kinase

Tissue Engineering

Induced Pluripotent Stem Cells

Molecular Docking

Top Venues

Journal of enzyme inhibition and medicinal chemistry

Chemical biology & drug design

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Ahmed H E Hassan, Waleed A Bayoumi, Selwan M El-Sayed, Trong-Nhat Phan, Taegeun Oh, Gyeongpyo Ham, Kazem Mahmoud, Joo Hwan No, Yong Sup Lee
Design, Synthesis, and Repurposing of Rosmarinic Acid-β-Amino-α-Ketoamide Hybrids as Antileishmanial Agents. Pharmaceuticals (Basel, Switzerland) 16 (11) (2023)
Ahmed H E Hassan, Waleed A Bayoumi, Selwan M El-Sayed, Trong-Nhat Phan, Yeon Ju Kim, Chae Hyeon Lee, Soo Bin Cho, Taegeun Oh, Gyeongpyo Ham, Kazem Mahmoud, Joo Hwan No, Yong Sup Lee
Rational repurposing, synthesis, in vitro and in silico studies of chromone-peptidyl hybrids as potential agents against Leishmania donovani . Journal of enzyme inhibition and medicinal chemistry 38 (1) (2023)
Ahmed H E Hassan, Waleed A Bayoumi, Selwan M El-Sayed, Trong-Nhat Phan, Yeon Ju Kim, Chae Hyeon Lee, Soo Bin Cho, Taegeun Oh, Gyeongpyo Ham, Kazem Mahmoud, Joo Hwan No, Yong Sup Lee
Rational repurposing, synthesis, in vitro and in silico studies of chromone-peptidyl hybrids as potential agents against Leishmania donovani . Journal of enzyme inhibition and medicinal chemistry 38 (1) (2023)
Ahmed H E Hassan, Waleed A Bayoumi, Selwan M El-Sayed, Trong-Nhat Phan, Yeon Ju Kim, Chae Hyeon Lee, Soo Bin Cho, Taegeun Oh, Gyeongpyo Ham, Kazem Mahmoud, Joo Hwan No, Yong Sup Lee
Rational repurposing, synthesis, in vitro and in silico studies of chromone-peptidyl hybrids as potential agents against Leishmania donovani . Journal of enzyme inhibition and medicinal chemistry 38 (1) (2023)
Basem Mansour, Waleed A Bayoumi, Magda A El-Sayed, Laila A Abouzeid, Mohammed A M Massoud
In vitro cytotoxicity and docking study of novel symmetric and asymmetric dihydropyridines and pyridines as EGFR tyrosine kinase inhibitors. Chemical biology & drug design 100 (1) (2022)